{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:41:43Z","timestamp":1790534503418,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Anal canal squamous cell carcinoma (ACSCC) is an exceedingly rare malignant neoplasm with challenges in sphincter preservation, treatment toxicities and long-term survival. Little is known concerning the activity of PD-1 antibodies in locally advanced ACSCC. This study reports on the efficacy and toxicities of a neoadjuvant PD-1 blockade combined with chemotherapy followed by concurrent immunoradiotherapy in ACSCC patients, and describes biomarkers expression and mutation signatures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this cohort study, patients were treated as planned, including four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent toripalimab. Multiplex immunofluorescence staining (mIHC) with PD-L1, CD8, CD163, Pan-Keratin and DAPI was performed with the pretreatment tumor tissue. Whole exome sequencing was performed for the primary tumor and peripheral blood mononuclear cells. The primary endpoint was the complete clinical response (cCR) rate at 3 months after overall treatment. Acute and late toxicities graded were assessed prospectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five female patients with a median age of 50 years old (range, 43-65 years old), finished treatment as planned. One patient had grade 3 immune related dermatitis. Two patients had grade 3 myelosuppression during neoadjuvant treatment. No severe radiation-related toxicities were noted. Four patients with PD-L1 expression &amp;gt;1% achieved a cCR after neoadjuvant treatment. and the other patient with negative PD-L1 expression also achieved a cCR at 3 months after radiotherapy. All the patients were alive and free from disease and had a normal quality of life, with 19.6-24 months follow up. Inconsistent expression of PD-L1 and CD163 was detected in 3 and 5 patients, respectively. TTN, POLE, MGAM2 were the top mutation frequencies, and 80 significant driver genes were identified. Pathway analysis showed enrichment of apoptosis, Rap1, Ras, and pathways in cancer signaling pathways. Eight significantly deleted regions were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This small cohort of locally advanced ACSCC patients had quite satisfactory cCR and sphincter preservation rate, after neoadjuvant PD-1 antibody toripalimab combined with chemotherapy followed by concurrent immunoradiotherapy, with mild acute and long-term toxicities.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.798451","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T04:24:34Z","timestamp":1642134274000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"WeiWei","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SuiHai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PeiQiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BaoQing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiFan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuanHong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the Treatment of Epidermoid Anal Cancer: 13-Year Follow-Up of the First Randomised UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid Anal Cancer: Results From the UKCCCR Randomised Trial of Radiotherapy Alone Versus Radiotherapy, 5-Fluorouracil, and Mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-Ordinating Committee on Cancer Research","volume":"348","year":"1996","journal-title":"Lancet (London England)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.ijrobp.2019.06.2544","article-title":"Executive Summary of the American Radium Society Appropriate Use Criteria for Treatment of Anal Cancer","volume":"105","author":"Russo","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, Mitomycin, and Radiotherapy vs Fluorouracil, Cisplatin, and Radiotherapy for Carcinoma of the Anal Canal: A Randomized Controlled Trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or Cisplatin Chemoradiation With or Without Maintenance Chemotherapy for Treatment of Squamous-Cell Carcinoma of the Anus (ACT II): A Randomised, Phase 3, Open-Label, 2 \u00d7 2 Factorial Trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and Antitumor Activity of the Anti-PD-1 Antibody Pembrolizumab in Patients With Recurrent Carcinoma of the Anal Canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for Previously Treated Unresectable Metastatic Anal Cancer (NCI9673): A Multicentre, Single-Arm, Phase 2 Study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"B9","article-title":"Anal Carcinoma, Version 1","volume-title":"NCCN Clinical Practice Guidelines in Oncology","author":"Benson","year":"2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Carcinoma of the Anal Canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2514","article-title":"Sensitive Detection of Somatic Point Mutations in Impure and Heterogeneous Cancer Samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/0471250953.bi1110s43","article-title":"From FastQ Data to High Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline","volume":"43","author":"Van der Auwera","year":"2013","journal-title":"Curr Protoc Bioinf"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: Efficient and Comprehensive Analysis of Somatic Variants in Cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nature12213","article-title":"Mutational Heterogeneity in Cancer and the Search for New Cancer-Associated Genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data","volume":"199","author":"Jurtz","year":"2017","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 Facilitates Sensitive and Confident Localization of the Targets of Focal Somatic Copy-Number Alteration in Human Cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477","article-title":"Signatures of Mutational Processes in Human Cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr483","article-title":"KOBAS 2.0: A Web Server for Annotation and Identification of Enriched Pathways and Diseases","volume":"39","author":"Xie","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks937","article-title":"TSGene: A Web Resource for Tumor Suppressor Genes","volume":"41","author":"Zhao","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1268","article-title":"TSGene 2.0: An Updated Literature-Based Knowledgebase for Tumor Suppressor Genes","volume":"44","author":"Zhao","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00845-13","article-title":"Sp100 Provides Intrinsic Immunity Against Human Papillomavirus Infection","volume":"4","author":"Stepp","year":"2013","journal-title":"mBio"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123600","article-title":"Modelling of Immune Checkpoint Network Explains Synergistic Effects of Combined Immune Checkpoint Inhibitor Therapy and the Impact of Cytokines in Patient Response","volume":"12","author":"Kondratova","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.02.042","article-title":"Long-Term Follow-Up of a Phase II Trial of High-Dose Radiation With Concurrent 5-Fluorouracil and Cisplatin in Patients With Anal Cancer (ECOG E4292)","volume":"81","author":"Chakravarthy","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil\/Mitomycin Versus Fluorouracil\/Cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1503713","article-title":"Late Gastrointestinal Toxicity After Radiotherapy for Anal Cancer: A Systematic Literature Review","volume":"57","author":"Pan","year":"2018","journal-title":"Acta Oncol (Stockholm Sweden)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24926","article-title":"The Ongoing Challenge of Large Anal Cancers: Prospective Long Term Outcomes of Intensity-Modulated Radiation Therapy With Concurrent Chemotherapy","volume":"9","author":"Hosni","year":"2018","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.05.018","article-title":"Anti-Epidermal Growth Factor Receptor Therapy in Combination With Chemoradiotherapy for the Treatment of Locally Advanced Anal Canal Carcinoma: Results of a Phase I Dose-Escalation Study With Panitumumab (FFCD 0904)","volume":"140","author":"Vendrely","year":"2019","journal-title":"Radiother Oncol"},{"key":"B28","article-title":"Treatment for Localized Anal Squamous Cell Carcinoma","author":"Jones","year":"2019"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of Overall Treatment Time on Survival and Local Control in Patients With Anal Cancer: A Pooled Data Analysis of Radiation Therapy Oncology Group Trials 87-04 and 98-11","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ijrobp.2004.03.034","article-title":"Epidermoid Anal Cancer: A Review of a Population-Based Series of 308 Consecutive Patients Treated According to Prospective Protocols","volume":"61","author":"Nilsson","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/jso.21866","article-title":"Is Neoadjuvant Chemotherapy Prior to Radio-Chemotherapy Beneficial in T4 Anal Carcinoma","volume":"104","author":"Moureau-Zabotto","year":"2011","journal-title":"J Surg Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant Nivolumab for Patients With Resectable HPV-Positive and HPV-Negative Squamous Cell Carcinomas of the Head and Neck in the CheckMate 358 Trial","volume":"9","author":"Ferris","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2017.05.001","article-title":"The Immune Microenvironment and HPV in Anal Cancer: Rationale to Complement Chemoradiation With Immunotherapy","volume":"1868","author":"Martin","year":"2017","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000343","article-title":"Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer","volume":"41","author":"Govindarajan","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/CMAR.S153965","article-title":"Programmed Death-Ligand 1 Expression Correlates With Diminished CD8+ T Cell Infiltration and Predicts Poor Prognosis in Anal Squamous Cell Carcinoma Patients","volume":"10","author":"Zhao","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.tranon.2021.101084","article-title":"A Clinical and Molecular Portrait of Non-Metastatic Anal Squamous Cell Carcinoma","volume":"14","author":"Iseas","year":"2021","journal-title":"Transl Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3441","article-title":"Clock-Like Mutational Processes in Human Somatic Cells","volume":"47","author":"Alexandrov","year":"2015","journal-title":"Nat Genet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-17-0060","article-title":"Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal","volume":"15","author":"Morris","year":"2017","journal-title":"Mol Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.humpath.2018.03.008","article-title":"Whole-Exome Sequencing Identified Mutational Profiles of Squamous Cell Carcinomas of Anus","volume":"80","author":"Shin","year":"2018","journal-title":"Hum Pathol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.144","article-title":"Mutational Analysis of Anal Cancers Demonstrates Frequent PIK3CA Mutations Associated With Poor Outcome After Salvage Abdominoperineal Resection","volume":"114","author":"Cacheux","year":"2016","journal-title":"Br J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127901","article-title":"Titin Mutation Associated With Responsiveness to Checkpoint Blockades in Solid Tumors","volume":"4","author":"Jia","year":"2019","journal-title":"JCI Insight"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84940","article-title":"Immune Activation and Response to Pembrolizumab in POLE-Mutant Endometrial Cancer","volume":"126","author":"Mehnert","year":"2016","journal-title":"J Clin Invest"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000881","article-title":"Somatic POLE Exonuclease Domain Mutations Elicit Enhanced Intratumoral Immune Responses in Stage II Colorectal Cancer","volume":"8","author":"Mo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-018-0039-1","article-title":"The Genomic Landscape of Small Cell Carcinoma of the Esophagus","volume":"28","author":"Wang","year":"2018","journal-title":"Cell Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.798451\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T04:24:43Z","timestamp":1642134283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.798451\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2021.798451"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.798451","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]},"article-number":"798451"}}